Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 10, Issue 6, 2011, Pages 428-434

  McNally, P ^a,c   Coughlan, C ^c   Bergsson, G ^c   Doyle, M ^a   Taggart, C ^c   Adorini, L ^b   Uskokovic, M R ^b   El Nazir, B ^a   Murphy, P ^a   Greally, P ^a   Greene, C M ^c   McElvaney, N G ^c  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b BioXell SpA   (Italy)

^c BEAUMONT HOSPITAL   (Ireland)

Author keywords

Children; Cholecalciferol; Cystic fibrosis; Inflammation; P. aeruginosa; Vitamin D; Vitamin d receptor agonist

Indexed keywords

CALCITRIOL; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; I KAPPA B ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; VITAMIN D RECEPTOR;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; INFLAMMATION; LUNG FIBROSIS; LUNG INFECTION; PSEUDOMONAS AERUGINOSA; RESPIRATORY EPITHELIUM; VITAMIN D DEFICIENCY;

CALCITRIOL; CELLS, CULTURED; CYSTIC FIBROSIS; EPITHELIAL CELLS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; RECEPTORS, CALCITRIOL; RESPIRATORY MUCOSA; VITAMINS;

EID: 81455158952     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.06.013     Document Type: Article

References (44)

1. Oppenheimer E.H., Esterly J.R. Pathology of cystic fibrosis review of the literature and comparison with 146 autopsied cases. Perspect Pediatr Pathol 1975, 2:241-278. 241-78.
2. Adorini L., Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol Aug. 2008, 4(8):404-412.
3. Sadeghi K., Wessner B., Laggner U., Ploder M., Tamandl D., Friedl J., et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol Feb. 2006, 36(2):361-370.
4. Xu H., Soruri A., Gieseler R.K., Peters J.H. 1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. Scand J Immunol Dec. 1993, 38(6):535-540.
5. Penna G., Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol Mar. 1 2000, 164(5):2405-2411.
6. D'Ambrosio D., Cippitelli M., Cocciolo M.G., Mazzeo D., Di L.P., Lang R., et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest Jan. 1 1998, 101(1):252-262.
7. van Halteren A.G., van Etten E., de Jong E.C., Bouillon R., Roep B.O., Mathieu C. Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes Jul. 2002, 51(7):2119-2125.
8. van E.E., Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol Oct. 2005, 97(1-2):93-101.
9. Boonstra A., Barrat F.J., Crain C., Heath V.L., Savelkoul H.F., O'Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol Nov. 1 2001, 167(9):4974-4980.
10. Moro J.R., Iwata M., von Andriano U.H. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol Sep. 2008, 8(9):685-698.
11. Suzuki T., Sano Y., Sotozono C., Kinoshita S. Regulatory effects of 1alpha,25-dihydroxyvitamin D(3) on cytokine production by human corneal epithelial cells. Curr Eye Res Feb. 2000, 20(2):127-130.
12. Xue M.L., Zhu H., Thakur A., Willcox M. 1 alpha,25-Dihydroxyvitamin D3 inhibits pro-inflammatory cytokine and chemokine expression in human corneal epithelial cells colonized with Pseudomonas aeruginosa. Immunol Cell Biol Aug. 2002, 80(4):340-345.
13. Equils O., Naiki Y., Shapiro A.M., Michelsen K., Lu D., Adams J., et al. 1,25-Dihydroxyvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin Exp Immunol Jan. 2006, 143(1):58-64.
14. Yim S., Dhawan P., Ragunath C., Christakos S., Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J Cyst Fibros Nov. 30 2007, 6(6):403-410.
15. Gombart A.F., Borregaard N., Koeffler H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J Jul. 2005, 19(9):1067-1077.
16. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science Mar. 24 2006, 311(5768):1770-1773.
17. Weber G., Heilborn J.D., Chamorro Jimenez C.I., Hammarsjo A., Torma H., Stahle M. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J Invest Dermatol May 2005, 124(5):1080-1082.
18. Wang T.T., Nestel F.P., Bourdeau V., Nagai Y., Wang Q., Liao J., et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol Sep. 1 2004, 173(5):2909-2912.
19. Kreindler J.L., Steele C., Nguyen N., Chan Y.R., Pilewski J.M., Alcorn J.F., et al. Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest Sep. 1 2010, 120(9):3242-3254.
20. Neville L.A., Ranganathan S.C. Vitamin D in infants with cystic fibrosis diagnosed by newborn screening. J Paediatr Child Health Jan. 2009, 45(1-2):36-41.
21. Rovner A.J., Stallings V.A., Schall J.I., Leonard M.B., Zemel B.S. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. Am J Clin Nutr Dec. 2007, 86(6):1694-1699.
22. Feranchak A.P., Sontag M.K., Wagener J.S., Hammond K.B., Accurso F.J., Sokol R.J. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr Nov. 1999, 135(5):601-610.
23. Stephenson A., Brotherwood M., Robert R., Atenafu E., Corey M., Tullis E. Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis. Am J Clin Nutr May 2007, 85(5):1307-1311.
24. Sokol R.J., Reardon M.C., Accurso F.J., Stall C., Narkewicz M., Abman S.H., et al. Fat-soluble-vitamin status during the first year of life in infants with cystic fibrosis identified by screening of newborns. Am J Clin Nutr Nov. 1989, 50(5):1064-1071.
25. Chavasse R.J., Francis J., Balfour-Lynn I., Rosenthal M., Bush A. Serum vitamin D levels in children with cystic fibrosis. Pediatr Pulmonol Aug. 2004, 38(2):119-122.
26. Kunzelmann K., Schwiebert E.M., Zeitlin P.L., Kuo W.L., Stanton B.A., Gruenert D.C. An immortalized cystic fibrosis tracheal epithelial cell line homozygous for the delta F508 CFTR mutation. Am J Respir Cell Mol Biol May 1993, 8(5):522-529.
27. Bruscia E., Sangiuolo F., Sinibaldi P., Goncz K.K., Novelli G., Gruenert D.C. Isolation of CF cell lines corrected at DeltaF508-CFTR locus by SFHR-mediated targeting. Gene Ther Jun. 2002, 9(11):683-685.
28. Mathieu C., Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med Apr. 2002, 8(4):174-179.
29. Cohen-Lahav M., Douvdevani A., Chaimovitz C., Shany S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol Mar. 2007, 103(3-5):558-562.
30. Cohen-Lahav M., Shany S., Tobvin D., Chaimovitz C., Douvdevani A. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol Dial Transplant Apr. 2006, 21(4):889-897.
31. Sun J., Kong J., Duan Y., Szeto F.L., Liao A., Madara J.L., et al. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab Aug. 2006, 291(2):E315-E322.
32. Vidyarani M., Selvaraj P., Jawahar M.S., Narayanan P.R. 1, 25 Dihydroxyvitamin D3 modulated cytokine response in pulmonary tuberculosis. Cytokine Nov. 2007, 40(2):128-134.
33. Sun J., Kong J., Duan Y., Szeto F.L., Liao A., Madara J.L., et al. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab Aug. 2006, 291(2):E315-E322.
34. Giarratana N., Penna G., Amuchastegui S., Mariani R., Daniel K.C., Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol Aug. 15 2004, 173(4):2280-2287.
35. Gilbert C.R., Arum S.M., Smith C.M. Vitamin D deficiency and chronic lung disease. Can Respir J May 2009, 16(3):75-80.
36. Black P.N., Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. Chest Dec 2005, 128(6):3792-3798.
37. Laaksi I., Ruohola J.P., Tuohimaa P., Auvinen A., Haataja R., Pihlajamaki H., et al. An association of serum vitamin D concentrations <40nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr Sep. 2007, 86(3):714-717.
38. Wayse V., Yousafzai A., Mogale K., Filteau S. Association of subclinical vitamin D deficiency with severe acute lower respiratory infection in Indian children under 5 y. Eur J Clin Nutr Apr. 2004, 58(4):563-567.
39. Wolfenden L.L., Judd S.E., Shah R., Sanyal R., Ziegler T.R., Tangpricha V. Vitamin D and bone health in adults with cystic fibrosis. Clin Endocrinol (Oxf) Sep. 2008, 69(3):374-381.
40. Abbott J., Dodd M., Webb A.K. Health perceptions and treatment adherence in adults with cystic fibrosis. Thorax Dec. 1996, 51(12):1233-1238.
41. Borowitz D., Wegman T., Harris M. Preventive care for patients with chronic illness. Multivitamin use in patients with cystic fibrosis. Clin Pediatr (Phila) Dec. 1994, 33(12):720-725.
42. Rias Llorente R.P., Bousono G.C., az Martin J.J. Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros Sep. 2008, 7(5):359-367.
43. Robinson D.M., Scott L.J. Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. Drugs 2005, 65(4):559-576.
44. Masuda S., Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol Cancer Ther Apr. 2006, 5(4):797-808.